Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

741. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis Full Text available with Trip Pro

the combination of published literature and national estimates. However, a single randomised controlled trial (the Prostate Cancer Prevention Trial) formed the key source of data (Thompson, et al. 2003, see ‘Other Publications of Related Interest’ below for bibliographic details). The clinical outcomes were incidence of prostate cancer, disease recurrence, chemoprevention-related side-effects (erectile dysfunction, loss of libido, and incontinence), treatment-related side-effects (impotence and incontinence (...) , et al. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care 2003;41:153-64. Mittmann N, Trakas K, Risebrough N, et al. Utility scores for chronic conditions in a community-dwelling population. Pharmacoeconomics 1999;15:369-76. Indexing Status Subject indexing assigned by NLM MeSH Cost-Benefit Analysis; Finasteride /therapeutic use; Humans; Incidence; Male; Markov Chains; Middle Aged; Prostatic Neoplasms /economics /prevention & Quality

2008 NHS Economic Evaluation Database.

742. Men treated for prostate cancer did not consider urinary, bowel, or sexual dysfunction as problems of health

Men treated for prostate cancer did not consider urinary, bowel, or sexual dysfunction as problems of health Men treated for prostate cancer did not consider urinary, bowel, or sexual dysfunction as problems of health | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Men treated for prostate cancer did not consider urinary, bowel, or sexual dysfunction as problems of health Article Text Qualitative Men treated for prostate cancer did

2008 Evidence-Based Nursing

743. Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study Full Text available with Trip Pro

Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study Calcium and dairy foods in relation to prostate cancer were examined in the National Institutes of Health (NIH)-AARP (formerly known as the American Association of Retired Persons) Diet and Health Study (1995/1996-2001). Diet was assessed with a food frequency questionnaire at baseline. Multivariate relative risks and 95% confidence intervals were estimated by Cox regression. During up to 6 (...) years of follow-up (n = 293,888), the authors identified 10,180 total prostate cancer cases (8,754 nonadvanced, 1,426 advanced, and 178 fatal cases). Total and supplemental calcium were unrelated to total and nonadvanced prostate cancer. However, a statistically nonsignificant positive association with total calcium was observed for advanced (> or = 2,000 vs. 500-<750 mg/day: relative risk (RR) = 1.25, 95% confidence interval (CI): 0.91, 1.71; p(trend) = 0.06) and fatal (> or = 1,000 vs. 500-<750 mg

2008 EvidenceUpdates

744. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. (Abstract)

Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. PURPOSE: To assess the benefit and toxicity and quality-of-life (QOL) outcomes of pelvic nodes irradiation in nonmetastatic prostate carcinoma patients. PATIENTS AND METHODS: Between December 1998 and June 2004, 444 patients with T1b-T3, N0 pNx, M0 prostate carcinoma were randomly assigned to either pelvic and prostate radiotherapy or prostate radiotherapy only. Patients were stratified (...) to the Radiation Therapy Oncology Group and Late Effects in Normal Tissues Subjective, Objective, Management, and Analytic scales, respectively. The QOL outcome was recorded with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, the International Prostatic Symptom Score, and the Sexual Function Index scales. RESULTS: With a 42.1-month median follow-up time, the 5-year PFS and overall survival were similar in the two treatment arms for the whole series

2008 EvidenceUpdates Controlled trial quality: uncertain

745. Guideline for the management of clinically localized prostate cancer: 2007 update.

Guideline for the management of clinically localized prostate cancer: 2007 update. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines and Measures Funding

2007 American Urological Association Education and Research, Inc.

746. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Full Text available with Trip Pro

of men who underwent radical prostatectomy for prostate adenocarcinoma from 1988 to 2006, using data from the databases of the Shared Equal Access Regional Cancer Hospital (n = 1373), Duke Prostate Center (n = 1974), and Johns Hopkins Hospital (n = 10 287). Multivariate linear regression models adjusting for clinicopathological characteristics were used to analyze the main outcome measures.Associations between BMI and mean adjusted PSA concentrations, mean plasma volume, and mean adjusted PSA mass (...) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. Recent studies have suggested that obese men have lower serum prostate-specific antigen (PSA) concentrations than nonobese men. Because men with higher body mass index (BMI) have greater circulating plasma volumes, lower PSA concentrations among obese men may be due to hemodilution.To determine the association between hemodilution and PSA concentration in obese men with prostate cancer.Retrospective study

2007 JAMA

747. PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. Full Text available with Trip Pro

of Gleason score 7 with tertiary grade 5 vs other Gleason scores with respect to time to prostate-specific antigen (PSA) failure in men with prostate cancer.From 1989 to 2005, 2370 men with clinical tumor category 1c to 3b, node-negative, and nonmetastatic prostate cancer underwent definitive therapy with surgery or radiation therapy with or without hormonal therapy. A pathologist with expertise in genitourinary cancers assigned Gleason scores to the prostate needle biopsy specimens. Cox regression (...) 6.7 years, respectively; adjusted hazard ratio (HR), 0.56; 95% confidence interval [CI], 0.32-0.97; P = .04) or score of 6 or less (median time, 15.4 years; adjusted HR, 0.24; 95% CI, 0.13-0.43; P < .001). However, a significant difference was not observed when these men were compared with men with Gleason score 8 to 10 disease (median time, 5.1 years; adjusted HR, 0.96; 95% CI, 0.54-1.71; P = .90).In this study population, men with prostate cancer having biopsy Gleason score 7 and tertiary grade

2007 JAMA

748. Cryotherapy for localised prostate cancer. Full Text available with Trip Pro

Cryotherapy for localised prostate cancer. Prostate cancer is a common cancer in elderly men and in some will prove fatal. Standard treatments for localised disease include surgery ( radical prostatectomy), radiotherapy and active monitoring. New emerging therapies are being evaluated with the aim of reducing the complication rate associated with standard therapies, as well as developing an effective treatment. One such modality is cryotherapy, a procedure that introduces probes directly (...) into the prostate tumour and kills the malignant cells by a freezing process.This review aims to evaluate the relative clinical and economic benefits of cryotherapy compared to standard therapies for the primary treatment of localised prostate cancer.Our search strategy included an electronic search of MEDLINE from 1996 to December 2006, plus EMBASE (Excerpta Medica Database), the Cochrane library, ISI Science Citation Index, Database of Abstracts and Reviews of Effectiveness (DARE), and LILACS to identify all

2007 Cochrane

749. Interstitial brachytherapy in localised prostate cancer

and quality of life in patients with localised prostate cancer as the only evidence of a benefit are insufficient to apply this therapeutic procedure, as potential harm regarding survival and disease-related symptoms cannot be excluded with sufficient certainty. We therefore urgently recommend the conduct of sound clinical studies in order to define the relevance of brachytherapy compared with other treatment options. Key words Low-dose-rate permanent interstitial brachytherapy, seed implantation (...) Interstitial brachytherapy in localised prostate cancer Executive Summary IQWiG Reports - Commission No. N04-02 Interstitial brachytherapy in localised prostate cancer 1 1 Translation of the executive summary of the final report “Interstitielle Brachytherapie beim lokal begrenzten Prostatakarzinom” (Version 1.0; Status: 17.01.2007). Publication date of translation: 19.03.2007. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German

2007 Institute for Quality and Efficiency in Healthcare (IQWiG)

750. Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study

Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study Brachytherapy versus prostatectomy in localized prostate cancer: results of a French multicenter prospective medico-economic study Buron C, Le Vu B, Cosset JM, Pommier P, Peiffert D, Delannes M, Flam T, Guerif S, Salem N, Chauveinc L (...) prostate cancer treatment. The authors concluded societal costs were similar, quality of life was generally worse with IB, and symptom profiles differed by intervention. The study was generally well reported and conducted. Missing data may affect the results. Survival data and longer follow-up would aid assessment of the comparative cost-effectiveness of the interventions. Type of economic evaluation Cost-effectiveness analysis Study objective The study evaluated health related quality of life (HRQoL

2007 NHS Economic Evaluation Database.

751. Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review

Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review Nursing interventions to improve the health of men with prostate cancer undergoing radiotherapy: a review Tarnhuvud M, Wandel C, Willman A CRD summary This review found evidence to support the use of nurse-led interventions, providing information on the side-effects of radiotherapy (...) , in men with prostate cancer. In view of the variability and relative poor quality of the included studies, along with the apparent selective reporting of the study findings, the authors' conclusions should be treated with caution. Authors' objectives To assess how nursing interventions can improve the health of men undergoing radiotherapy for prostate cancer. Searching MEDLINE, CINAHL and the Cochrane Library were searched for articles published from January 1994 to May 2006; the search terms were

2007 DARE.

752. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Health Technology Assessment 2007; 11(2): 1-198 Original Paper URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents /economics /therapeutic use; Drug Therapy, Combination; Glucocorticoids /economics /therapeutic use; Models, Economic; Neoplasm Metastasis /drug therapy; Prednisone /economics /therapeutic use; Prostatic Neoplasms /drug therapy; Quality-Adjusted Life (...) A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical

2007 DARE.

753. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. A systematic review and economic model of the clinical (...) effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer. Collins R, Fenwick E, Trowman R, Perard R, Norman G, Light K, Birtle A, Palmer S, Riemsma R. Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Collins R, Fenwick E, Trowman R, Perard R

2007 Health Technology Assessment (HTA) Database.

754. Intensity modulated radiation therapy (IMRT) for localized prostate cancer

radiation therapy (IMRT) for localized prostate cancer. Boston: Institute for Clinical and Economic Review (ICER). 2007 Authors' objectives

To appraise the comparative clinical effectiveness and comparative value of IMRT versus 3DCRT in the treatment of localized prostate cancer.

Project page URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Prostatic Neoplasms /pathology /radiotherapy; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated /methods Language Published English (...) Intensity modulated radiation therapy (IMRT) for localized prostate cancer Intensity modulated radiation therapy (IMRT) for localized prostate cancer Intensity modulated radiation therapy (IMRT) for localized prostate cancer Pearson SD, Ladapo J, Prosser L Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pearson SD, Ladapo J, Prosser L. Intensity modulated

2007 Health Technology Assessment (HTA) Database.

755. Interstitial brachytherapy in localised prostate cancer

as disease-specific and disease-free survival, no evidence is available to demonstrate a superiority or equivalence of brachytherapy versus prostatectomy or radiotherapy. Therefore, the potential advantages of brachytherapy with regard to organ function and quality of life in patients with localised prostate cancer as the only evidence of a benefit are insufficient to apply this therapeutic procedure, as potential harm regarding survival and disease-related symptoms cannot be excluded with sufficient (...) Interstitial brachytherapy in localised prostate cancer Interstitial brachytherapy in localised prostate cancer Interstitial brachytherapy in localised prostate cancer Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut fuer Qualitaet und Wirtschaftlichkeit im

2007 Health Technology Assessment (HTA) Database.

756. Dose Verification System (DVS) for patients undergoing radiotherapy for breast and prostate cancer: horizon scanning technology briefing

Dose Verification System (DVS) for patients undergoing radiotherapy for breast and prostate cancer: horizon scanning technology briefing Dose Verification System (DVS) for patients undergoing radiotherapy for breast and prostate cancer: horizon scanning technology briefing Dose Verification System (DVS) for patients undergoing radiotherapy for breast and prostate cancer: horizon scanning technology briefing National Horizon Scanning Centre Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Horizon Scanning Centre. Dose Verification System (DVS) for patients undergoing radiotherapy for breast and prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2007 Authors' objectives This study examines the use of a Dose Verification System (DVS) for patients undergoing radiotherapy

2007 Health Technology Assessment (HTA) Database.

757. Indium In 111 Capromab Pendetide (ProstaScint) radioimmunoscintigraphy for the diagnosis of prostate cancer

with prostate cancer who are at high risk for metastasis or recurrence of the disease. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Prostatic Neoplasms /diagnosis; Radioimmunodetection Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email (...) . Citation Indium In 111 Capromab Pendetide (ProstaScint) radioimmunoscintigraphy for the diagnosis of prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2007 Authors' objectives Indium In 111 capromab pendetide (ProstaScint; Cytogen Corporation), also known as CYT-356, is an indium-111-labeled monoclonal antibody that recognizes a specific cytoplasmic membrane antigen on prostatic carcinoma cells. Indium In 111 capromab pendetide is used as a diagnostic imaging agent in patients

2007 Health Technology Assessment (HTA) Database.

758. Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. Full Text available with Trip Pro

of prostate cancer were detected (2.3%) with eight having at least two positive results in biopsy cores and three showing perineural invasion. One tumour was of high volume (cT2c), Gleason score 7, with a positive result on digital rectal examination; nine tumours were cT1c, Gleason score 6, and eight had a negative result on digital rectal examination. Five of the nine eligible participants (55%) agreed to be randomised. No biochemical disease progression in the form of a rising prostate specific antigen (...) Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. To investigate the feasibility of testing for prostate cancer and the prevalence and characteristics of the disease in unselected young men.Prospective cohort nested within a randomised controlled trial, with two years of follow-up.Eight general practices in a UK city.1299 unselected men aged 45-49.Prostate biopsies for participants with a prostate specific antigen level of 1.5

2007 BMJ

759. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? Full Text available with Trip Pro

escalation using proton beans? Clin Oncol 2003;15:S10-5. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-9. Indexing Status Subject indexing assigned by NLM MeSH Adenocarcinoma /economics /radiotherapy; Aged; Cost-Benefit Analysis; Disease-Free Survival; Humans; Male; Markov Chains; Middle Aged; Prostatic Neoplasms /economics (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined proton beam therapy and intensity-modulated radiation therapy (IMRT) for the treatment of prostate cancer. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of male patients diagnosed with intermediate-risk adenocarcinoma of the prostate

2007 NHS Economic Evaluation Database.

760. Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective Kobayashi T, Goto R, Ito K, Mitsumori K Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of personalised re-screening strategies for prostate cancer. Strategies were based on individual baseline levels of prostate-specific antigen (PSA

2007 NHS Economic Evaluation Database.